Stephen Freedland, MD, of Cedars-Sinai, discussed enzalutamide and leuprolide's potential to improve overall survival without sacrificing quality of life in prostate cancer.
Stephen Freedland, MD
Advertisement
Stephen Freedland, MD, is director of the Center for Integrated Research in Cancer and Lifestyle and associate director for training and education at the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai.
Articles by Stephen Freedland, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Government Shutdown Concluded but ACA Subsidies in Limbo
2
5 AI and Digital Health Advances Transforming Breast Cancer Care and Research
3
2025 Hypertension Guideline Updates Presented at AHA Scientific Sessions
4
Can a Coffee a Day Keep AFib Away?
5
